Greycoat Research helps cats enjoy healthier and longer lives byallowing them to overcome feline kidney disease.
What is feline kidney disease?
Cats are born with a hereditary disorder that makes them particularly susceptible to kidney disease.
Due to this defect, the protein known as AIM cannot become activated in their bodies.
As AIM plays a vital role in helping the body remove waste, this defect leads to the accumulation of waste inside a cat’s body, which causes damage to its kidneys.
Cats with feline kidney disease experience a loss of both appetite and energy.
Kidney problems eventually extend to other organs in the body and inevitably lead to complications.
Cats with feline kidney disease may develop and suffer from a wide range of complications, ranging from thyroid problems and diabetes to heart and pancreatic complications.
They gradually and slowly waste away, deteriorating to the point where they can no longer even swallow a mouthful of water, and ultimately meet their end.
Until now, feline kidney disease was considered both an inevitable and incurable disease.
Can feline kidney disease be overcome?
Greycoat Research believes a clue can be found in the AIM protein.
The AIM protein was first discovered by Japan’s Dr. Miyazaki Toru.
The protein serves as a marker that assists in the cleanup of waste within the body.
However, cats are born with inherently lower AIM activation rates than other animals, making them more susceptible to kidney disease.
Based on these facts, Dr. Miyazaki Toru was able to uncover the mechanism behind feline kidney disease, which had long remained an unsolvable mystery.
Furthermore, Dr. Miyazaki Toru and Greycoat Research determined that triggering the activation of the AIM in a cat’s body could prevent it from developing feline kidney disease or, in the case of cats already suffering from kidney disease, allow the disease to be managed more safely.
Based on these findings, Greycoat Research is now focusing on the development of drugs and supplements to help treat and manage feline kidney disease.
Case Studies
TT was first diagnosed with stage 2 feline kidney disease in 2019 at the age of 5.
The average life expectancy of a cat with stage 2 kidney disease is 1 year.
However, with the aid of supplements developed by Greycoat Research, TT remains as healthy and active as ever even now, in 2024.
Greycoat Research’s Kidney Disease Supplements for Cats
Dr. Toru Protocol Active
Dr. Toru Protocol Active triggers the activation of the AIM protein in your cat’s body to facilitate the cleanup of waste in their bodies. The supplement is ideal for both preventing feline kidney disease and managing the health of cats who are already in the early stages of feline kidney disease.
Dr. Toru Protocol Intensive
Dr. Toru Protocol Intensive is the culmination of cutting-edge bio-research dedicated to ensuring kidney health in cats. It contains components that trigger AIM activation, replenishes vitamins, and aids the activation of SIRT1, which possesses anti-oxidation and anti-cellular aging properties.
Dr. Toru Protocol Intensive can be administered alongside Dr. Toru Protocol Active to help care for cats with stage 1, 2, and 3 feline kidney disease.
Dr. Toru Protocol Treats
Dr. Toru Protocol Treats is a chicken-based treat that contains an amino acid complex derived from Dr. Toru Protocol.
The product utilizes freeze-drying techniques to ensure that the AIM activating components can be safely and efficiently absorbed into a cat’s body, and is flavored to ensure that even the pickiest of cats will have no reservations about enjoying them as a delicious snack.
Greycoat Research Group
Greycoat Research’s Mission
To ensure a healthier, happier, and longer life for cats!
- English
- 한국어 (Korean)
- 日本語 (Japanese)
- ไทย (Thai)
- Deutsch (German)
- 中文 (Chinese)
- Bahasa Indonesia (Indonesian)